ALB and neoplasm: In our study, the S,R-valine–citrulline noncleavable linker only exhibited moderateactivity in vivo (half potency relative to the cleavable S,S-valine–citrulline linker), which likely resultedfrom a toxic MMAE–catabolite generated during lysosomal activity.We also demonstrated the preferential tumor biodistribution of ourhomogeneous albumin conjugates, as well as their biocompatibility,with no associated toxicity or side effects.